MARCO

Across TCGA pan-cancer cohorts, MARCO Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated MARCO data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MARCO Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MARCO expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, KIRP, and ESCA are the cancer types where MARCO Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.271	0.606	.016	15	view →
KIRP	DFS	Median	All	0.157	0.867	<.001	12	view →
ESCA	OS	Median	III,IV	0.108	0.574	<.001	12	view →
LUSC	DFS	Median	III,IV	0.168	0.663	.003	12	view →
PRAD	OS	Median	All	0.174	0.883	<.001	12	view →
LIHC	DFS	Median	All	0.081	0.546	<.001	12	view →
UCEC	DFS	Median	III,IV	1.000	0.536	.025	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
SCLC	OS	Median	All	0.301	0.656	.036	6	view →
SARC	DFS	Median	All	0.179	0.594	.031	3	view →
SKCM	OS	Median	III,IV	0.535	0.854	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MARCO–BLCA (OS)

Open the BLCA breakdown →